Thoughts on all the NCCN preferred second-line DLBCL regimens, other than CAR-T and transplant

The challenges of targeting BRCA mutations in all cancers

Tumor lineage shapes BRCA-mediated phenotypes: https://pmc.ncbi.nlm.nih.gov/articles/PMC7048239/

Thoughts on using pCR as a surrogate endpoint

DESTINY-Breast11: https://pubmed.ncbi.nlm.nih.gov/41130363/

Clinical Cancer Research publication on pCR, EFS and OS: https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant

BMJ publication on pCR, EFS and OS: https://www.bmj.com/content/375/bmj-2021-066381

FDA-sponsored analysis: https://pubmed.ncbi.nlm.nih.gov/24529560/

KATHERINE trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1814017

Episode explaining the Fc receptor on antibodies, with some examples!

Lessons from TIGIT antibodies: https://pubmed.ncbi.nlm.nih.gov/41389708/

Discussion on the CIRCULATE trial

ASCO CIRCULATE abstract: https://www.asco.org/abstracts-presentations/260542

Real-world experience of circulating tumor DNA testing in resectable colorectal cancer: a Japanese single-institution observational study: https://pmc.ncbi.nlm.nih.gov/articles/PMC12847216/

ASCO GI abstract: Pathologic determinants of ctDNA-shedding in colorectal cancer metastases. https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.183

Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables https://www.sciencedirect.com/science/article/pii/S0169500202001721

Why it's hard to compare adverse events across trials

Capitello-291: https://www.nejm.org/doi/full/10.1056/NEJMoa2214131

Capitello-281:

https://pubmed.ncbi.nlm.nih.gov/41120017/

RASolute 302:https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

What we do and do not understand about antibody drug conjugate sequencing.

Journal of Thoracic Oncology: https://www.jto.org/article/S1556-0864(26)00007-9/fulltextPost mortem sacituzumab govitecan study:https://pmc.ncbi.nlm.nih.gov/articles/PMC8495771/

Why HRR gene mutations are not the perfect biomarker.

PROpel trial: thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00382-0/fulltext

TALAPRO-2 trial: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract

TRITON-3 trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2214676

Some thoughts on how to interpret ctDNA trials that look to validate it as a predictive biomarker